With the meaning of Good Health Innovation Technology, we domestically manufacture and sell respiratory-related products that are dependent on imports in the medical and sports fields. Currently, we are supplying our products to major hospitals, welfare centers, and public health centers, and are striving to improve the health of our customers by operating breathing enhancement and rehabilitation programs using them. In the future, we are working to build a system that will enable remote medical treatment by building a platform related to breathing. • 2022 - Patent registration for respiratory muscle strengthening device mask - MIP/MEP patent registration - Spirometry patent registration • 2021 - MIP / MEP electromagnetic compatibility certification (KC), UV sterilization box electromagnetic compatibility certification (KC) - MDA Malaysia medical device certification - Innovative product designation certification (IMT/PEP) - FDA certification - 5 items • 2020 - Obtained ISO 13485 certification - Obtained CE certification (medical device) - Stored in online shopping malls in 6 European countries • 2019 - FDA certified - Report on manufacturing and sales of medical devices (Japan) - Medical device manufacturing notification (IMT) - Participated in Osaka Medical Equipment Exhibition

In a fiercely competitive market of innovation, UWS's team of experts is a partner that leads customers to success. • 2023. - Became a member of KoDWA (Korea Digital Wellness Association) - Patent application - 'Server, Method and Computer program for providing hybrid wallet based account solution' (Patent app No: 10-2023-0066014) - Capital increased to 11 billion KRW - Trademark: "KRDC (Korea Digital Currency)" (Trademark No.: 40-1983587) • 2022. - Became a member of CNCF(Cloud Native Computing Foundation) - SK Inc. - established MSA-based work system operation outsourcing contract Initiated Blockchain-based Carbon Emission Monitoring Solutions - KB Financial Group - MSA-based private cloud "KB one-cloud" development - SK TELECOM - Hadoop-Hive-based DBM System & AWS EMR-Hive-based application migration • 2021. - LG Chemicals - MS Azure-based ERP system replication/shared file/restoration system development - MetLife - Cloud preliminary assessment consulting SKOn (China/Hungary/USA battery factory production line expansion) - replication/shared file/restoration system development - Eduvation - AWS-based PaaS (Platform-as-a-Service) development

Artificial intelligence technology that saves lives. Waysen, a medical AI specialist company, is moving forward to develop technology that goes beyond the world's best artificial intelligence technology and can be useful in medical settings and contribute to the valuable work of saving lives. • 2023 - WAYMED Endo No. 37 designated as innovative medical device - Supplied WAYMED Endo to Gangneung Asan Hospital - Selected for NVIDIA Startup Upbringing Program (N-UP) - Selected as a future unicorn company by the Ministry of Science and ICT - WAYMED Endo level 3 medical device certification (KFDA) - Minister of Health and Welfare Award - Winner of 4 CES 2023 Innovation Awards • 2022 - Selected as one of the top 1000 national innovative companies - Selected as Medtech Innovator APAC Top 4 - Weisen-Gangbuk Samsung Hospital, St. Paul's Hospital AI Gastroenterology Endoscopy Collaboration Pilot Project - Panic disorder DTX was finally selected for the pan-ministry full-cycle medical device research and development project - Weisen-Gangbuk Samsung Hospital selected as pilot project for overseas expansion of ICT-based medical system - Research paper on lung cancer metastasis detection using AI published in TLCR, an international journal - CES innovation awards 2022 Health & Wellness category - WAYMED endo (stomach/colon) medical device grade 2 acquired • 2021 - Selected as a heterogeneous technology convergence project by the head of the Korea Institute of Industrial Technology Evaluation and Planning - Waysen - Kangbuk Samsung Hospital promotes joint research on AI-based chronic disease care plan - Selected for Microsoft Startup Program

iMediSync has developed the world's first gender-separated database of healthy people of all ages and iSyncBrain, a cloud platform for automatically analyzing brainwaves and heart rate variability with artificial intelligence. iSyncBrain consists of automatic noise removal based on artificial intelligence, extraction of brain wave indicators from sensors and sources, provision of simple and detailed reports for comparison of healthy people, and group analysis functions for research. A biomarker called iSyncBrain-M1 was added through a clinical trial conducted by the Ministry of Food and Drug Safety for early detection of mild cognitive impairment with memory impairment. Currently, biotechnology can be used to check whether amyloid, the causative agent of Alzheimer's, is deposited, whether recovery from coma, cognitive impairment after stroke, alpha-synuclein, the causative agent of Parkinson's disease, and EEG phenotype of depression. Joint research to develop markers is actively underway. Recently, iSyncWave, an innovative 19-channel dry EEG/pulse wave measurement and digital therapy convergence device, was developed and combined with the iSyncBrain software platform. As a digital treatment, neuro biofeedback will be added to personalized near-infrared therapy. • 2023 - Entry-level iSyncWave scheduled to be released - Obtained international standard certification (ISO 13485) for medical device quality management system (March 2023) - iSyncBrain-C software medical device FDA certification (2023.03) - Participating in CES 2023 • 2022 - Selected as an excellent design product (Good Design) and awarded by the Minister of SMEs and Startups - 4IR Awards (4th Industrial Revolution Awards) Biohealth Category Grand Prize - iSyncWave 510K approved (2022.08) - iSyncWave selected as innovative prototype by Public Procurement Service (2022.06) - iSyncBrain MCI Classifier evaluation deferred new medical technology selection (May 2022) - Won Red Dot Design Award - Participating in CES 2022 • 2021 - Attracted Series C (KRW 7.6 billion) - Obtained iSyncWave medical device certification (December 2021) - Obtained GMP for iSyncWave manufacturing (November 2021) - Selected as an innovative product for the second half of the year by the Public Procurement Service

Established in 1977 based on the belief that “manufacturing, which is the foundation of national industry, drives the economy,” Deogyang Industry has been producing automobile interior parts such as cockpit modules and door trims for the past 40 years, and has become a leading company in the parts industry. I am proud that I have fulfilled my mission. Now, we are going one step further and preparing for a new leap forward by concentrating our accumulated capabilities on promoting new electrification businesses to satisfy customers that meet the needs of the future eco-friendly automobile era. • 2023 - Dedicated to the ‘Hall of Fame’ for companies with excellent national quality competitiveness (Ministry of Trade, Industry and Energy) - DYIC (Deogyang Innovation Center) established • 2022 - Received a commendation from the Minister for ‘Contribution to Materials, Components, and Equipment Technology Development’ - Received a commendation from the minister for ‘contribution to fostering regional representative mid-sized companies’ - MOU with Kolon Plastics on ‘Development of lightweight vehicle and battery flame-retardant composite materials’ - Awarded 10 times as a company with excellent national quality competitiveness (Ministry of Trade, Industry and Energy) - Signed MOU for marine ESS package system (Hanwha Defense) - Achieved 5-star rating for win-win cooperation (Hyundai Motors) - Achieved 5-star technology rating (Hyundai Motor Company) - Achieved 5-star quality rating (Hyundai Motor Company) • 2021 - Awarded ‘700 Million Dollar Export Tower’ on Trade Day (Korea International Trade Association) - Korea Industrial Technology R&D Daejeon Prime Minister Award (Ministry of Trade, Industry and Energy) - Awarded 9th National Quality Competitiveness Excellent Company (Ministry of Trade, Industry and Energy)

Golden Hour Co., Ltd. has developed disaster rescue products that can maximize the efficiency of rescue activities by reducing rescue time while rescuing as many rescuers as possible due to the reduction in rescue personnel. Starting with the popularization of this developed product, the right to survival of disaster-vulnerables is guaranteed by reducing the risk factors of casualties in facilities vulnerable to evacuation during disasters and emergencies, and human lives are saved by presenting a new paradigm for lifesaving in national or social disaster situations. We will do our best to grow into a social entrepreneur who values more. • 2022 - Technology patent and design registration in 4 countries (Japan, Europe, USA, Korea) - KTR no detection of hazardous substances and issuance of a test report suitable for performance evaluation - European medical device certification - Quality management system certification - ESG report completed - Selected as a global procurement marketer - B2B online platform selection - Selected as Korea Compass Business Matching Support Project - Selection of trial purchase products for the 2nd technology development product trial purchase system - Entered Dongbang Growth Mall (selected products for public purchase) - Launched on UN procurement site - Social Venture Impact IR Minister of SMEs and Startups Award Grand Prize - Selected as Minister of Public Administration and Security Award at Korea Safety Technology Awards - KOICA INNO-LAB A Program Award - Participated in an on-site meeting of the Osong Advanced Medical Industry Promotion Foundation - Selected for corporate growth support program - Selected as a global technology commercialization project - Selected for data voucher support project - Selected as a support project for Chungbuk IP Narae Program • 2021 - Confirmation of start-up company and certification - Selected as a new safety technology by Korea Occupational Safety and Health Agency - Establishment of own factory with direct production confirmation - Won the Korea Best Brand Award - Commendation for industrial accident victims - Won the Excellence Award at Ulsan University Hospital Medical Competition - Selected for corporate growth support program - Selected as a global technology commercialization project - Selected for data voucher support project - Selected as a support project for Chungbuk IP Narae Program • 2020 - Preliminary social enterprise certification - Medical device certification and manufacturing license - Certified as a social venture company - Venture Nara innovative prototype certification - Certification of corporate research institute - Selection of Social Impact Changers - Credit Guarantee Fund Startup NEST - LG Social Campus local innovator “Local Value Up 3rd Group” in Cheongju - KEPCO KDN Social Economy Enterprise “Global Star Company Development Support Project” - Designated as venture startup innovation procurement product 2019 - Innovative technology product manufacturing startup partners “Presidential participation” - Social entrepreneur development project - Korea University X-GARAGE prototype maintenance - Establishment of Golden Hour Corporation

• Exiting Biz : Trading Pharma - Finished products - API (raw materials) - License-In and Out Production Activity - Foods, Medical - Devices Cosmetics - Patch and ODF(Oral Film) > The company's stable profit base • New Biz Fields : Europran Pharmaceutical Patch Production - Own Slovenian GMP Patch Production Facility - Exporting EU,USA for several Medicinal Patch - Own Marketing Cosmetics and Foods in Korea and China and Taiwan(strengthen Brand Power) > Securing a bridgehead for entering the European/North American pharmaceutical market > Korea’s first overseas pharmaceutical production base • R&D Pipe Lines : Innovatives - Lidocaine 5% patch(1* generic target) - Nail Antifungal patch - Lidocaine Facial patch - Lbuprofen OTC patch > Combinded IONTOPHOREIS > Products available for licensing out ・2019 - Tadalafil OOF technology transfer agreement signed with Italian Pedia Pharmaceuticals ・2017-2018 - Received the Minister of Health and Welfare Award - Opening of Slovenia’s own pharmaceutical production base - Establishment of Woosin Lapache - Selected as an excellent product at the Seoul Awards ・2015-2016 - Received the 10 Million Dollar Export Tower Award - Acquisition of Slovenian pharmaceutical factory - Acquisition of medical device manufacturing license - Acquired quasi-drug manufacturing license ・2013-2014 - Established its own production plant, ‘Incheon Songdo Rabotachi’ - Establishment of Wooshin Hungary - Obtained food manufacturing license - Cosmetic manufacturing and sales business license registration ・2005~2012 - Relocation of headquarters to Guro Digital Complex in Seoul - Establishment of our own R&D center composed of masters and doctors of pharmacy - Independent development of hydrogel patch ・1992-2004 - Wooshin Rabotachi Establishment/CEO Nam Taek-su (Pharmacist License Number: 31051) - Obtained pharmaceutical export license - Obtain ISO Certificate